Innovations In Clinical Neuroscience

HOTTOP Multiple Sclerosis MAR 2018

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link:

Contents of this Issue


Page 19 of 23

R E V I E W 20 Hot Topics in Multiple Sclerosis [March 2018] 61. Rudick RA, Lee JC, Nakamura K, Fisher E. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci. 2009;282:106–11. 62. Lavorgna L, Bonavita S, Ippolito D, et al. Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study. Mult Scler. 2014;20:220–6. 63. Bendfeldt K, Hofstetter L, Kuster P, et al. Longitudinal gray matter changes in multiple sclerosis–differential scanner and overall disease- related effects. Hum Brain Mapp. 2012;33:1225–45. 64. Favaretto A, Lazzarotto A, Poggiali D, et al. MRI-detectable cortical lesions in the cerebellum and their clinical relevance in multiple sclerosis. Mult Scler. 2016;22:494–501. 65. Bakshi R, Benedict RH, Bermel RA, Jacobs L. Regional brain atrophy is associated with physical disability in multiple sclerosis: semiquantitative magnetic resonance imaging and relationship to clinical findings. J Neuroimaging. 2001;11:129–36. 66. Horakova D, Dwyer MG, Havrdova E, et al. Gray matter atrophy and disability progression in patients with early relapsing remitting multiple sclerosis: a 5-year longitudinal study. J Neurol Sci. 2009;282:112–9. 67. Filippi M, Preziosa P, Copetti M, et al. Gray matter damage predicts the accumulation of disability 13 years later in MS. Neurology. 2013;81:1759–67. 68. Nijeholt GJ, van Walderveen MA, Castelijns JA, et al. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain. 1998;121(Pt 4):687–97. 69. Liu C, Edwards S, Gong Q, et al. Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1999;66:323– 30. 70. Brex PA, Leary SM, O'Riordan JI, et al. Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001;70:544–7. 71. Evangelou N, DeLuca GC, Owens T, Esiri MM. Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions. Brain. 2005;128:29– 34. 72. Gilmore CP, Bo L, Owens T, et al. Spinal cord gray matter demyelination in multiple sclerosis—a novel pattern of residual plaque morphology. Brain Pathol. 2006;16:202–8. 73. Gilmore CP, Donaldson I, Bo L, et al. Regional variations in the extent and pattern of gray matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep gray matter nuclei and the spinal cord. J Neurol Neurosurg Psychiatry. 2009;80:182–7. 74. Rashid W, Davies GR, Chard DT, et al. Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study. J Neurol Neurosurg Psychiatry. 2006;77:51– 5. 75. Furby J, Hayton T, Anderson V, et al. Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis. Mult Scler. 2008;14:1068–75. 76. Rocca MA, Horsfield MA, Sala S, et al. Multicentre assessment of cervical cord atrophy among MS clinical phenotypes. Neurology. 2011;76:2096–102. 77. Lukas C, Sombekke MH, Bellenberg B, et al. Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. Radiology. 2013;269:542–52. 78. Losseff NA, Webb SL, O'Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain. 1996;119(Pt 3):701–8. 79. Amato MP, Bartolozzi ML, Zipoli V, et al. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology. 2004;63:89–93. 80. Amato MP, Portaccio E, Goretti B, et al. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol. 2007;64:1157–61. 81. Morgen K, Sammer G, Courtney SM, et al. Evidence for a direct association between cortical atrophy and cognitive impairment in relapsing-remitting MS. NeuroImage. 2006;30:891–8. 82. Benedict RH, Ramasamy D, Munschauer F, et al. Memory impairment in multiple sclerosis: correlation with deep gray matter and mesial temporal atrophy. J Neurol Neurosurg Psychiatry. 2009;80:201–6. 83. Benedict RH, Hulst HE, Bergsland N, et al. Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients. Mult Scler. 2013;19:1478–84. 84. Till C, Ghassemi R, Aubert-Broche B, et al. MRI correlates of cognitive impairment in childhood-onset multiple sclerosis. Neuropsychology. 2011;25:319–32. 85. Schoonheim MM, Geurts J, Wiebenga OT, et al. Changes in functional network centrality underlie cognitive dysfunction and physical disability in multiple sclerosis. Mult Scler. 2014;20:1058–65. 86. Schoonheim MM, Meijer KA, Geurts JJ. Network collapse and cognitive impairment in multiple sclerosis. Front Neurol. 2015;6:82. 87. Batista S, Zivadinov R, Hoogs M, et al. Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol. 2012;259:139–46. 88. Calabrese M, Agosta F, Rinaldi F, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsingremitting multiple sclerosis. Arch Neurol. 2009;66:1144–50. 89. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet.

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - HOTTOP Multiple Sclerosis MAR 2018